Immunohistochemical staining for S100P, SMAD4, and IMP3 on cell block preparations is sensitive and highly specific for pancreatic ductal adenocarcinoma.

作者: Jacob Sweeney , Rema Rao , Elizabeth Margolskee , Abha Goyal , Jonas J. Heymann

DOI: 10.1016/J.JASC.2018.07.002

关键词:

摘要: Introduction The diagnosis of pancreatic ductal adenocarcinoma (PDA) on endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) material is often challenging. An immunohistochemical (IHC) panel may help establish the PDA in cases limited by sample size or ambiguous cytology. S100P, IMP3, and SMAD4 are 3 IHC markers that have shown promise as individual for never been tested together a panel. In this study, we evaluated combined efficacy detection PDA. Materials Methods staining was performed cell blocks (CBs) procured from EUS-FNA procedures. cohort included CBs were diagnostic (n = 35), suspicious but nondiagnostic 2), well with benign epithelium 12) reactive 18). A positive result IMP3 S100P defined moderate strong >10% cells. Complete lack nuclear considered result—any negative result. Results Two marker panels almost always more specific than markers. Positivity at least 2 sensitive (91.89%) highly (100%) Conclusions composed Future studies should evaluate atypical cases.

参考文章(23)
Lola Rahib, Benjamin D. Smith, Rhonda Aizenberg, Allison B. Rosenzweig, Julie M. Fleshman, Lynn M. Matrisian, Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States Cancer Research. ,vol. 74, pp. 2913- 2921 ,(2014) , 10.1158/0008-5472.CAN-14-0155
Rhonda K Yantiss, Bruce A Woda, Gary R Fanger, M Kalos, Giles F Whalen, Hiroomi Tada, Dana K Andersen, Kenneth L Rock, Karen Dresser, KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. The American Journal of Surgical Pathology. ,vol. 29, pp. 188- 195 ,(2005) , 10.1097/01.PAS.0000149688.98333.54
Terry Lok, Lihong Chen, Fan Lin, Hanlin L. Wang, Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma. Human Pathology. ,vol. 45, pp. 394- 400 ,(2014) , 10.1016/J.HUMPATH.2013.10.004
Asif Ali, Victoria Brown, Simon Denley, Nigel B Jamieson, Jennifer P Morton, Colin Nixon, Janet S Graham, Owen J Sansom, C Ross Carter, Colin J McKay, Fraser R Duthie, Karin A Oien, Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel BMC Clinical Pathology. ,vol. 14, pp. 35- 35 ,(2014) , 10.1186/1472-6890-14-35
Andrew Renshaw, Comprehensive Cytopathology, 3rd Ed. Advances in Anatomic Pathology. ,vol. 16, pp. 433- ,(2009) , 10.1097/PAP.0B013E3181A9AD0B
Rhonda K. Yantiss, Ediz Cosar, Andrew H. Fischer, Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta Cytologica. ,vol. 52, pp. 133- 138 ,(2008) , 10.1159/000325470
Chihiro Gandou, Kenichi Harada, Yasunori Sato, Saya Igarashi, Motoko Sasaki, Hiroko Ikeda, Yasuni Nakanuma, Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules. Human Pathology. ,vol. 44, pp. 811- 821 ,(2013) , 10.1016/J.HUMPATH.2012.08.004
Haolin Hu, Qi Zhang, Chenfei Huang, Yi Shen, Xundi Chen, Xin Shi, Wenhao Tang, Diagnostic value of S100P for pancreatic cancer: a meta-analysis Tumor Biology. ,vol. 35, pp. 9479- 9485 ,(2014) , 10.1007/S13277-014-2461-4